Justin Greiwe, MD

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

Confirming Tapinarof’s Efficacy and Safety Across Atopic Dermatitis Severities, with Justin Greiwe, MD

Tapinarof was well-tolerated and demonstrated consistent efficacy across body regions in people as young as 2 years old with atopic dermatitis, according to data from the phase 3 ADORING 1 and 2 trials presented by Justin Greiwe, MD, Bernstein Allergy Group, and Clinical Assistant Professor of Medicine, Division of Immunology, Allergy, and Rheumatology, University of Cincinnati, at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California.

Greiwe and colleagues found that in ADORING 1, least squares (LS) mean overall EASI score improvements were –8.4 vs –4.1 (P <.0001) at week 8 and in ADORING 2, LS mean overall EASI score improvements were –10.1 vs –5.2 (P <.0001). By body region, LS mean changes in EASI scores by body region at Week 8 were: head/neck –8.7 vs –4.4 (ADORING 1) and –8.8 vs –4.7 (ADORING 2); trunk –5.9 vs –2.6 (ADORING 1) and –7.2 vs –3.8 (ADORING 2); upper extremities –12.0 vs –5.2 (ADORING 1) and –15.0 vs –6.6 (ADORING 2); and lower extremities –8.6 vs –4.4 (ADORING 1) and –9.9 vs –5.5 (ADORING 2; all P <.0001). Tapinarof was well tolerated across sensitive areas, including the face/neck.

 spoke with Greiwe to learn more about tapinarof, which is a topical aryl hydrocarbon receptor agonist, the efficacy and safety findings from the ADORING 1 and 2 trials, and how it could potentially benefit patients with atopic dermatitis under the age of 2 years.

“I think with some of these new advancements and new indications, we're slowly moving into the pediatric realm, which, to be honest, is really important, because this is a group that typically suffers a lot and tends to have pretty refractory severe disease,” Greiwe said.

Tapinarof is currently FDA-approved under the name Vtama for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

Greiwe J, Tallman A, Sublett JW, et al. Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down To 2 Years Of Age With Atopic Dermatitis. Presented at: 2025 AAAAI/WAO Joint Congress, February 28-March 3. Abstract 595

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older. News release. Organon. December 16, 2024. Accessed March 5, 2025. https://www.organon.com/news/fda-approves-vtama-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older/

Justin Greiwe, MD

Articles